Dual specificity Tyrosine (Y) Regulated Kinase (DYRK1A) is an attractive target for therapeutic drug development due to its roles during embryonic development and in major human pathological conditions including Down syndrome (DS), Alzheimer’s disease (AD), and cancer, which are summarized in these excellent recent reviews (Atas-Ozcan et al., 2021; Kumar et al., 2021; Laham et al., 2021; Deboever et al., 2022; Rammohan et al., 2022; Santos-Duran and Barreiro-Iglesias, 2022). The gene discussed is DYRK1A; the disease is Dravet syndrome.